Can You Stop Herpes From Spreading to Partners? Yes, With Limits

You can substantially reduce the risk of passing herpes to a partner, but no strategy on the market drives it to zero. Daily antiviral therapy cuts transmission by about half, consistent condom use cuts it by roughly half again, and avoiding sex during outbreaks removes the highest-risk windows. Layering these measures pushes annual transmission risk into the low single digits for most couples. The details below explain why each layer works, where it fails, and what the numbers actually mean.

The biology of asymptomatic shedding

Herpes spreads through skin-to-skin contact with virus that reaches the surface. The critical mechanism is that this happens on days with no visible symptoms. After primary infection, the virus retreats into sensory nerve ganglia and reactivates intermittently, traveling back down nerve fibers to the skin. Reactivation often produces no sores because the immune system contains it at the surface; the virus is present for hours to a few days before being cleared.

This silent shedding is the engine of transmission. Studies of genital HSV-2 showed virus detectable on roughly 10 to 20 percent of days in the first year after infection, and about 15 percent of days overall on average. Most of those days had no lesions. That single fact explains why "we only avoid sex during outbreaks" fails as a strategy: the majority of transmission events occur when neither partner sees anything wrong.

Shedding frequency declines over time. People infected for more than two years shed less often than those in their first year, though it never stops entirely. This is why long-standing couples sometimes report transmission after years of unprotected sex, and why newer infections carry higher risk to partners.

How much each measure cuts risk

The numbers here come from randomized trials and large cohort studies, and they matter because they let couples reason about combined protection rather than guess.

Daily valacyclovir or acyclovir suppressive therapy reduced HSV-2 transmission to susceptible partners by about 48 percent in a landmark trial of discordant couples. Condoms reduced transmission by about 30 to 50 percent per act of intercourse, with one large study finding roughly 50 percent protection for HSV-2 when used consistently. Combining the two compounds the benefit: roughly half the risk from therapy, then half again from condoms, landing near 70 to 75 percent overall reduction.

Avoiding sex during symptomatic outbreaks removes a disproportionate share of risk because lesion days carry far higher viral loads than asymptomatic days. Studies estimate that a substantial minority of transmissions, often cited around 50 percent, come from symptomatic periods despite those periods being a small fraction of time.

Acyclovir is inexpensive, often under USD 30 per month in generic form in the US; valacyclovir runs higher. Suppression is off-label for some formulations but standard practice and supported by major guidelines.

What the risk looks like over a year

Transmission risk is easier to grasp as an annual probability than as a per-act figure.

These are population averages, not guarantees. Individual risk depends on infection duration, shedding patterns, immune status, and sexual practices. Sex of the susceptible partner matters: female partners face higher risk from male-to-female transmission than the reverse, largely due to mucosal surface area.

Edge cases that change the calculus

Several situations bend the general numbers in ways couples should understand.

New infections are the riskiest. In the first 6 to 12 months after acquiring HSV-2, shedding frequency and viral load are highest, so a partner recently infected poses more risk than one infected for a decade. Waiting until shedding settles and starting suppression early makes sense.

HSV-1 genital infections behave differently. Genital HSV-1 sheds far less often than HSV-2 and transmits to partners less readily, though oral-to-genital transmission of HSV-1 is now a leading cause of new genital herpes in many settings. A partner with cold sores can transmit to genitals through oral sex even without a visible sore.

Mixing infection types matters. Someone with existing HSV-1 has partial protection against acquiring HSV-2, which changes counseling for couples with mismatched histories.

Pregnancy is its own scenario. Transmission to a newborn during delivery carries serious risks, and management around delivery follows distinct obstetric protocols. This warrants dedicated discussion with an obstetric provider rather than general discordant-couple advice.

Red-flag situations that warrant prompt clinical input:

A pregnant partner near delivery with active genital lesions A partner with compromised immunity (transplant, chemotherapy, advanced HIV) New genital lesions accompanied by fever, severe pain, or urinary retention Suspected infection in a newborn: lethargy, poor feeding, or blisters in the first weeks of life Recurrent outbreaks that are not responding to standard suppression

Misconceptions that raise real risk

The most costly misconception is that no sore means no risk. Because most shedding is asymptomatic, relying on symptom checks alone leaves couples exposed to the majority of transmission opportunities. This is the single largest gap between what people believe and what the data show.

A second misconception is that suppression eliminates transmission. It roughly halves it. Couples who drop condoms after starting antivirals and assume the problem is solved actually move backward on total protection. The counterintuitive professional point: antiviral therapy does not sterilize the virus, and its benefit is probabilistic, not absolute.

A third is that herpes testing is part of routine screening. It is not. Standard sexually transmitted infection panels often omit HSV, and blood tests have real limitations near the window of recent infection. A partner who says they tested negative may simply never have been tested for herpes.

A fourth is that condoms fail against herpes because it spreads skin-to-skin. Condoms do not cover all skin, which is why protection is partial rather than complete. But partial protection is real and measurable, not negligible.

Practical steps that actually reduce spread

The actions below turn the mechanism and the numbers into something a couple can do this week.

Step 1: Know the infection type and timing. Confirm whether it is HSV-1 or HSV-2 and roughly when it was acquired. Shedding frequency and risk differ sharply by type and by time since infection.

Step 2: Start daily suppressive therapy if transmission risk matters. Standard approaches use daily antivirals, and the decision should be made with a clinician who can weigh benefits and costs. Generic options often keep monthly cost under USD 30.

Step 3: Use condoms consistently, not intermittently. Partial protection compounds with therapy, and consistency is where most of the benefit lives.

Step 4: Treat visible outbreaks as high-risk windows. Abstain from genital contact from the first tingle or lesion until complete healing, typically 7 to 10 days for a recurrence.

Step 5: Disclose early and normalize the conversation. Disclosure lets partners make informed choices, and it is associated with lower risk because couples plan rather than react.

Step 6: Reassess after a year. Shedding declines over time, and couples can revisit condom use and suppression decisions with better information.

Timeline: what to expect after starting measures

The limits, stated plainly

No combination eliminates risk. The best-layered approach leaves a residual annual transmission risk in the range of 1 to 2 percent for many couples, and higher for newly infected or immune-compromised situations. That residual is real, not a rounding error.

The evidence base also has gaps. Most transmission trials enrolled heterosexual HSV-2 discordant couples, so data for same-sex couples and genital HSV-1 rely more on shedding studies than on transmission outcomes. Shedding is a proxy for risk, not a perfect one.

Suppressive therapy does not cure infection and stops when it stops being taken. Missed doses restore shedding toward baseline within days.

The honest framing for couples is this: herpes transmission can be reduced by roughly 70 to 75 percent with combined measures, which is substantial and worth doing, but it cannot be made impossible. Disclosure and shared planning remain the most durable protections, because they keep both partners engaged in the measures that work.